Abstract: A method for predicting disease is provided. The method includes generating biased analyte data by adding analyte sensor bias to historical analyte data, associating the biased analyte data with clinical disease diagnoses associated with the historical analyte data, and extracting features from the biased analyte data. The method further includes, for each model of a number of models, generating disease predictions based on different combinations of the features extracted from the biased analyte data, and evaluating the disease predictions based on the clinical disease diagnoses associated with the biased analyte data. The method further includes selecting a model and a combination of features based on a performance metric and a robustness metric.

Abstract: Techniques for data analysis and user guidance are provided. One or more current measurements of one or more current analyte levels for the user are received from a sensor. A pattern is generated based on the one or more current measurements and the one or more past measurements. A first alignment with a first user target is then determined based on the pattern, where the first user target relates to one or more of a mental state or physical state of the user. A first result is output to the user, based on the determined first alignment.

Abstract: Techniques for data analysis and user guidance are provided. One or more current measurements of one or more current analyte levels for the user are received from a sensor. A pattern is generated based on the one or more current measurements and the one or more past measurements. A first alignment with a first user target is then determined based on the pattern, where the first user target relates to one or more of a mental state or physical state of the user. A first result is output to the user, based on the determined first alignment.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Systems and methods for detecting and reporting patterns in analyte concentration data are provided. According to some implementations, an implantable device for continuous measurement of an analyte concentration is disclosed. The implantable device includes a sensor configured to generate a signal indicative of a concentration of an analyte in a host, a memory configured to store data corresponding at least one of the generated signal and user information, a processor configured to receive data from at least one of the memory and the sensor, wherein the processor is configured to generate pattern data based on the received information, and an output module configured to output the generated pattern data. The pattern data can be based on detecting frequency and severity of analyte data in clinically risky ranges.

Abstract: Disease prediction using analyte measurements and machine learning is described. In one or more implementations, a combination of features of analyte measurements may be selected from a plurality of features of the analyte measurements based on a robustness metric and a performance metric of the combination, and a machine learning model may be trained to predict a health condition classification using the combination. The performance metric may be associated with an accuracy of predicting the health condition classification, and the robustness metric may be associated with an insensitivity to analyte sensor manufacturing variabilities on the accuracy. Once trained, the machine learning model predicts the health condition classification for a user based on analyte measurements of the user collected by a wearable analyte monitoring device. The combination of features may be extracted from the analyte measurements of the user and input into the machine learning model to predict the classification.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Techniques for data analysis and user guidance are provided. One or more current measurements of one or more current analyte levels for the user are received from a sensor. A pattern is generated based on the one or more current measurements and the one or more past measurements. A first alignment with a first user target is then determined based on the pattern, where the first user target relates to one or more of a mental state or physical state of the user. A first result is output to the user, based on the determined first alignment.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: The invention provides a polyester bicomponent staple fiber comprising poly(trimethylene terephthalate) and at least one polymer selected from the group consisting of poly(ethylene terephthalate), poly(trimethylene terephthalate), and poly(tetramethylene terephthalate) or a combination of such members, said bicomponent staple fiber having: a) a scalloped oval cross-section shape having an aspect ratio a:b of about 2:1 to about 5:1 wherein ‘a’ is a fiber cross-section major axis length and ‘b’ is a fiber cross-section minor axis length; b) a polymer interface substantially perpendicular to the major axis; c) a cross-section configuration selected from the group consisting of side-by-side and eccentric sheath-core; d) a plurality of longitudinal grooves; and e) a groove ratio of about 1.05:1 to about 1.9:1. Additionally, the invention provides a spun yarn comprising cotton and the polyester bicomponent staple fiber of the invention, as well as fabrics and garments comprising the spun yarn of the invention.

Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4, n W, X and Y are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

Abstract: This invention relates to pyrazole derivatives of formula (I) 1

Abstract: A melt spinning process and the nylon hollow filaments and yarns made by such process which includes extruding molten nylon polymer having a relative viscosity (RV) of at least about 50 and a melting point (T.sub.M) of about 210.degree. C. to about 310.degree. C. from a spinneret capillary orifice with multiple orifice segments providing a total extrusion area (EA) and an extrusion void area (EVA) such that the fractional extrusion void content, defined by the ratio [EVA/EA] is about 0.6 to about 0.95, and the extent of melt attenuation, defined by the ratio [EVA/(dpf).sub.S ], is about 0.05 to about 1.5, in which (dpf).sub.S is the spun denier per filament, the (dpf).sub.S being selected such that the denier per filament at 25% elongation (dpf).sub.25 is about 0.

Abstract: A method and system for separating and "unmixing" prerecorded and mixed right and left stereo sound input signals into three (3) or more output sound signals for sound reproduction by three or more loudspeakers spaced apart and located forward of a listener or listeners. The output sound signals are linear combinations of the right and left sound input signals and uniquely satisfy conditions of sound linearity, symmetry, uniformity, normality, integrity, balance, constancy, and fidelity to create a substantially more accurate sound image of the recorded performance than that created by reproducing only the stereophonic sound input signals.